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ABSTRACT
Pigmented purpuric dermatosis is a chronic benign skin disorder of unknown aetiology. Although there are several other potential cofactors, 
drugs are the most frequent cause. This paper describes the case of a 71-year-old woman who was admitted in the emergency department 
with skin lesions on the lower extremities, characteristics of Schamberg's disease. After a medical study and treatment, it was concluded 
that the lesions were caused by amlodipine administration. To the authors’ knowledge, only one previous case describing an association 
between this disease and amlodipine administration has been reported in the medical literature.
LEARNING POINTS
• Schamberg's disease is the most common form of pigmented purpuric dermatosis.
• The condition can be caused by amlodipine administration.




Pigmented purpuric dermatoses (PPD) are chronic, benign and relapsing skin disorders of unknown aetiology[1]. They are characterized by 
the presence of petechiae, purpura and hyperpigmentation, that can be either asymptomatic or pruritic[1]. The lesions are mostly seen on the 
lower limbs but may occur anywhere on the body. There are five different types of PPD with the most common being Schamberg's disease 
(SD), which is also known as progressive pigmentary purpura[2, 3].
CASE REPORT
A 71-year-old woman was admitted in the emergency department with skin lesions on the lower extremities. She had petechial 
asymptomatic lesions which had evolved over 5 days, her medical history included hypertension, atrial fibrillation and dyslipidaemia, and 
she was chronically medicated with nebivolol 5 mg once a day, simvastatin 20 mg once a day, olmesartan 20 mg once a day, dabigatran 110 
mg twice a day, amlodipine 5 mg once a day and omeprazole 20 mg once a day. She had no history of recent medication adjustment. There 
were no significant changes in complete blood count, erythrocyte sedimentation rate (ESR) or prothrombin, and there was only a slight 
increase in the partial prothrombin time (50.8 sec) due to the ingestion of dabigatran. She was referred to the outpatient clinic of the internal 
medicine department where she was instructed to stop dabigatran and omeprazole and to start taking prednisolone 20 mg once a day and 
rivaroxaban 20 mg once a day.
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The patient was observed 1 month later by which time the skin lesions had progressively worsened (Fig. 1). The results of blood examinations 
including a full blood count, peripheral blood smear, coagulation screen and ANA, did not show any changes but the partial prothrombin 
time (32.1 sec) had normalized. On the same day, the patient was examined in the dermatology department, where it was confirmed that the 
lesions were compatible with PPD and topical corticoid was prescribed. The patient was evaluated 15 days later but the lesions remained 
the same. At this point, an extensive review of the medical literature was carried out and one article [4] was found that described SD caused 
by amlodipine administration, indicating that the patient should stop taking the drug, which she did. The patient’s lesions had improved 1 
week later and disappeared after 1 month (Fig. 2). At 6-month follow-up, the patient was still not taking amlodipine and remained without 
skin lesions.
Figure 1. Skin lesions compatible with Schamberg´s disease Figure 2. Skin lesions after cessation of amlodipine
DISCUSSION
SD was first described in 1901 by Jay Frank Schamber[5]. it is one of the five recognized clinical patterns of PPD which present a similar 
histopathology: SD, purpura annularis telangiectodes, lichen aureus, pigmented purpuric lichenoid dermatosis and eczematid-like purpura 
of Doucas and Kapetanakis[1]. 
PPD is more frequent in men and can occur at any age. SD is mostly asymptomatic except for slight pruritus that can occasionally occur, and 
characteristically, the lesions present as pinhead-sized reddish puncta that further form irregular plaques of orange or brown pigmentation.
There are three different hypotheses regarding the pathogenesis of PPD: capillary fragility, humoral immunity and cellular immunity[2]. 
In most cases of PPD the aetiology is unknown[1,2,6]. However, several important cofactors influence disease presentation: venous 
hypertension[7], exercise[2] and gravitational dependency[7, 8], capillary fragility[2], focal infections[9] and chemical ingestion[8].
The literature reports that drugs are the most frequent causative factor in PPD, especially in SD[1]. The drugs that cause PPD are 
acetaminophen, aspirin, adalin, carbromal, chlordiazepoxide, glipizide, glybuzole, hydralazine, meprobamate, persantin, reserpine, thiamine, 
interferon-alfa and medroxyprogesterone acetate injection[1]. The authors found one article[4] in the literature that associated SD with the 
administration of amlodipine.
As there are no medical interventions of proven benefit for this skin condition[1], symptomatic treatment is recommended through the use 
of topical corticosteroids and histamines for the pruritus[2,7,9]. Other treatments such as psoralen photochemotherapy[10], griseofulvin[11], 
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pentoxifylline[12,13], cyclosporine[14], rutoside and ascorbic acid[6,15] have been suggested.
According to the literature, SD is characterized by the skin alteration described above and by a normal haematological profile and coagulation 
tests, conditions that were observed in our patient.
Taking into account the clinical presentation, the resolution of the skin condition with the suspension of amlodipine and the fact that 
correct treatment had been administered without effect, in our opinion the skin alteration in this case was associated with amlodipine 
administration. Moreover, other authors have reported one case where SD was associated with the administration of amlodipine[4].
In conclusion, further investigation should be considered to develop a better understanding of the possible correlation between amlodipine, 
a drug used daily, and PPD. In the meantime, bearing in mind that there are two cases describing an association between SD and amlodipine, 
we recommend early amlodipine discontinuation in patients who present with PPD in order to prevent progression of the skin lesions. 
Moreover, exhaustive and careful evaluation of the characteristics of the medications that each patient takes chronically is important, 
especially patients in polypharmacy, as such analysis may not only prevent these situations but also allow their early resolution.
This article is equally intended to draw physicians’ attention to the importance of recognizing this disease because patients are frequently 
disturbed by its appearance. Physicians who are unaware of these findings will subject the patient to multiple, extensive and unnecessary 
examinations to exclude an underlying disease such as vasculitis, coagulopathy or associated haematological malignancy. 
